In microarray gene expression experiments, several diverse conditions in each experiment (e.g., time, doses, replicates) increase the data points from tens of thousands of measurements for a single ...

Microarrays first appeared on the scene around 1995, and it was not long before their use became quite widespread. Early analyses were modelled on those of the pioneers. By around 2000, however, ...

Although the superiority of expression-based biomarkers, as compared with traditional clinical staging, has been disputed, 33 a nationwide clinical trial is under way in the Netherlands in which ...

Pancreatic ductal adenocarcinoma (PDAC) is an important cause of malignancy-related death. In the United States, it ranks fifth among the leading causes of cancer death, accounting for approximately ...

PHOENIX, August 16, 2004-5AM Solutions, a software solution provider enabling biomedical research, today announced the release of Microarray Enterprise Manager TM (MEM). The solution was delivered in ...

As a graduate student, Eric Olson learned something about DNA microarrays: Biochip data management can be vexing. His graduate adviser abandoned a number of microarray experiments because it was too ...

The study of microbial communities from environmental samples, known as metagenomics, has been propelled forward by technological advancements in high-throughput sequencing such as 454’s Genome ...

SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced the release of the latest versions of its VIA™ and Solve™ software for genomic data analysis and ...

This study aims to identify potential biomarkers of hepatocellular carcinoma (HCC) occurrence/recurrence and obesity, along with the molecular mechanisms that involve these biomarkers. Three ...

Genomatix Software GmbH today announced that it has achieved GeneChip-compatible TM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has ...

The research community's rapid acceptance of microarrays notwithstanding, technical challenges remain. Biochip developers continue to grapple with these issues while upgrading their offerings and ...